Tenofovir Gel Confirmed To Be Effective Against Herpes In Lab Experiment, Study Shows

Data from lab experiments published online by the journal Cell Host and Microbes last week show that the gel form of the antiretroviral tenofovir, which is being investigated as an HIV prevention method, works to inhibit the reproduction of herpes virus in tonsil and cervical tissue, the New York Times reports.

The study was conducted to help confirm findings from a Centre for the AIDS Programme of Research in South Africa (CAPRISA) clinical trial released last year at the International AIDS Conference in Vienna that showed the gel reduced the risk of HIV infection among women who used it by 39 percent and the risk of contracting herpes by 51 percent, according to the newspaper. The latest study was performed by researchers from NIH, Gilead Sciences Inc. and universities in Belgium and Italy, the Times notes (McNeil, 10/20).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

The Henry J. Kaiser Family Foundation Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KaiserFamilyFoundation | twitter.com/kff

Filling the need for trusted information on national health issues, the Kaiser Family Foundation is a nonprofit organization based in San Francisco, California.